Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis
about
Do disparities between populations in randomized controlled trials and the real world lead to differences in outcomes?New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs).Rapid liver and spleen stiffness improvement in compensated advanced chronic liver disease patients treated with oral antivirals.Pharmacogenetics of ribavirin-induced anemia in hepatitis C.
P2860
Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis
description
2015 nî lūn-bûn
@nan
2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Effectiveness and safety of fi ...... atients with advanced fibrosis
@ast
Effectiveness and safety of fi ...... atients with advanced fibrosis
@en
type
label
Effectiveness and safety of fi ...... atients with advanced fibrosis
@ast
Effectiveness and safety of fi ...... atients with advanced fibrosis
@en
prefLabel
Effectiveness and safety of fi ...... atients with advanced fibrosis
@ast
Effectiveness and safety of fi ...... atients with advanced fibrosis
@en
P2093
P2860
P356
P1476
Effectiveness and safety of fi ...... atients with advanced fibrosis
@en
P2093
Alhambra Spanish Study Group
Ana Belén Martín
Carmen Vinaixa
Conrado Fernández
Dolores Espinosa
Francisco Javier Rodriguez
Francisco Jorquera
Isabel Carmona
Javier Salmerón
P2860
P304
P356
10.3748/WJG.V21.I30.9163
P407
P577
2015-08-01T00:00:00Z